🔗 Permalink

Inventor profile of:

Brian Murphy

City:

Fort Collins, Colorado

Country:

United States

Published Applications:

Last publication date:

2021-01-14

Top Assignees for applications by Brian Murphy

The entities that hold a legal rights for patent applications filed by inventor Murphy Brian:

Coherus Biosciences, Inc. 27 Redwood City, CA United States
Coherus Biosciences, Inc. 1 Redwood, CA United States

Recent patent applications by Murphy Brian

Brian Murphy from Fort Collins, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2021-01-14

US20210007991A1

Human necessities

ETANERCEPT FORMULATIONS EXHIBITING MARKED REDUCTION IN SUB-VISIBLE PARTICLES

#2 | 2020-12-31

US20200405865A1

Human necessities

ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL

#3 | 2019-11-14

US20190343955A1

Human necessities

Etanercept formulations stabilized with sodium chloride

#4 | 2019-11-07

US20190336601A1

Human necessities

Etanercept Formulations Stabilized with Sodium Chloride

#5 | 2019-10-31

US20190328875A1

Human necessities

ETANERCEPT FORMULATIONS STABILIZED WITH MEGLUMINE

#6 | 2019-10-17

US20190314500A1

Human necessities

Etanercept Formulations Stabilized with Sodium Chloride

#7 | 2019-10-17

US20190314499A1

Human necessities

Etanercept Formulations Stabilized with Sodium Chloride

#8 | 2019-10-17

US20190314498A1

Human necessities

Etanercept Formulations Stabilized with Sodium Chloride

#9 | 2019-10-03

US20190298837A1

Human necessities

Method of reducing formation of etanercept aggregates or fragments

#10 | 2019-09-26

US20190290768A1

Human necessities

Stable aqueous etanercept composition

#11 | 2019-09-26

US20190290767A1

Human necessities

Method of reducing formation of etanercept aggregates or fragments

#12 | 2019-09-26

US20190290766A1

Human necessities

Stable aqueous etanercept composition

#13 | 2019-09-26

US20190290765A1

Human necessities

Method of Reducing Formation of Etanercept Aggregates or Fragments

#14 | 2019-07-18

US20190216930A1

Human necessities

Etanercept formulations stabilized with amino acids

#15 | 2019-06-20

US20190184017A1

Human necessities

Etanercept formulations stabilized with xylitol

#16 | 2018-07-12

US20180193463A1

Human necessities

Etanercept formulations stabilized with combinations of sugars and polyols

#17 | 2018-05-10

US20180125982A1

Human necessities

Etanercept formulations stabilized with metal ions

#18 | 2018-02-01

US20180028668A1

Human necessities

Etanercept formulations stabilized with xylitol

#19 | 2016-11-03

US20160317667A1

Human necessities

Etanercept formulations stabilized with xylitol

#20 | 2016-07-14

US20160199489A1

Human necessities

Etanercept formulations stabilized with combinations of sugars and polyols

#21 | 2015-07-16

US20150196645A1

Human necessities

Stable aqueous formulations of etanercept

#22 | 2015-05-07

US20150125532A1

Human necessities

Etanercept formulations exhibiting marked reduction in sub-visible particles

#23 | 2013-05-02

US20130108634A1

Human necessities

Etanercept formulations stabilized with meglumine

#24 | 2013-05-02

US20130108633A1

Human necessities

Etanercept formulations stabilized with metal ions

#25 | 2013-05-02

US20130108632A1

Human necessities

Etanercept formulations stabilized with amino acids

#26 | 2013-04-25

US20130101640A1

Human necessities

Etanercept formulations stabilized with combinations of sugars and polyols

#27 | 2013-04-25

US20130101584A1

Human necessities

Etanercept formulations stabilized with xylitol

#28 | 2013-04-25

US20130101583A1

Human necessities

Etanercept formulations stabilized with sodium chloride

InventorID:

209034 ⎘